论文部分内容阅读
目的探讨中剂量阿糖胞苷（ＩＤ－Ａｒａ－Ｃ）对急性髓细胞性白血病（ＡＭＬ）的治疗效果。方法用ＩＤ－Ａｒａ－Ｃ方案对４６例ＡＭＬ患者进行化疗，其中用于完全缓解（ＣＲ）后强化治疗３６例，用于难治、复发ＡＭＬ诱导缓解治疗１０例。结果强化治疗组中位ＣＲ期为１６（３～５６）个月；预期３ａ和４ａ无病生存率（ＤＦＳ）分别为４９．７％及３３．１％。２例（２０％）难治、复发ＡＭＬ病人取得ＣＲ。结论ＩＤ－Ａｒａ－Ｃ用于ＡＭＬ的强化治疗能延长病人的ＤＦＳ，降低复发率；用于难治、复发ＡＭＬ的治疗也有一定效果。
Objective To investigate the effect of middle dose cytarabine (ID-Ara-C) on acute myeloid leukemia (AML). Methods 46 patients with AML were treated with ID-Ara-C regimen. Among them, 36 patients were treated with complete remission (CR) followed by intensive therapy and 10 patients with refractory and relapsed AML induced remission. Results The median duration of CR in the intensive treatment group was 16 (3 to 56) months; the disease-free survival rates (DFS) of 3a and 4a were expected to be 49.7% and 33.1%, respectively. Two patients (20%) with refractory or relapsed AML achieved CR. Conclusion ID-Ara-C for intensive treatment of AML can prolong the patient’s DFS and reduce the recurrence rate. The treatment of refractory and relapsed AML also has some effect.